CN101623276A - Compound radix salviae miltiorrhizae essence capsule for treating apoplexy and preparation technique thereof - Google Patents
Compound radix salviae miltiorrhizae essence capsule for treating apoplexy and preparation technique thereof Download PDFInfo
- Publication number
- CN101623276A CN101623276A CN200910022908A CN200910022908A CN101623276A CN 101623276 A CN101623276 A CN 101623276A CN 200910022908 A CN200910022908 A CN 200910022908A CN 200910022908 A CN200910022908 A CN 200910022908A CN 101623276 A CN101623276 A CN 101623276A
- Authority
- CN
- China
- Prior art keywords
- paeonol
- salviae miltiorrhizae
- radix salviae
- extraction
- raw material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
The invention aims to extract high-purity radix salviae miltiorrhizae essence and paeonol raw material from radix salviae miltiorrhizae and peony barks respectively and prepare a capsule preparation. The radix salviae miltiorrhizae essence raw material with the content greater than 95.0% is extracted and obtained by carrying out techniques of supercritical CO2 extraction, concentration, liquor alkalization, alcohol deposition, concentration, water leaching, concentration, precipitation, extraction, concentration, ether extraction, PH value regulation, recrystallization and the like on the radix salviae miltiorrhizae; a micro-capsule is prepared by adopting a gelatin encapsulation method, which is sealed and preserved in a dark place. The paeonol raw material with the content greater than 96.0% is prepared and obtained by carrying out techniques of pulverization, immersion, ultrasonic sound, distilling, cold storage, crystallization, recrystallization and the like on the peony barks; paeonol inclusion compound is prepared from beta-cyclodextrin, which is kept in a dark place and preserved in a closed way. The radix salviae miltiorrhizae essence micro-capsule and the paeonol inclusion compound are evenly mixed according to the proportion of 1:1 of the actual weight percentage and are encapsulated. The product promotes blood circulation, relieves the stasis of blood, disperses pathogenic wind, resolves phlegm, dredges the channels and activates the collaterals; the product mainly treats diseases, such as apoplexy (cerebral thrombus) and the like. 2-3 capsules are taken each time, and the capsules are taken for 2-3 times in one day; 4 weeks form one treatment course.
Description
Affiliated technical field
The present invention system extracts high-purity salvianic acid A and paeonol raw material respectively from Radix Salviae Miltiorrhizae, Cortex Moutan, and is prepared into the compound radix salviae miltiorrhizae essence capsule preparation process technology of treatment apoplexy, belongs to pharmaceutical chemistry, pharmaceutical preparation and clinical practice field thereof.
Background technology
Radix Salviae Miltiorrhizae is the dry root of labiate Radix Salviae Miltiorrhizae (Salvia miltiorrhiza Bunge), is that chemical constitution study compares deep a kind of Chinese medicine.Its bitter in the mouth, cold nature, GUIXIN, liver two warps have stasis-dispelling and pain-killing, promoting blood circulation to restore menstrual flow, the effect of the relieving restlessness that clears away heart-fire is the blood-activating and stasis-removing of using always.Wherein important water soluble ingredient danshensu has multiple pharmacologically active, comprises thrombosis, control hepatic fibrosis and the effects such as antiinflammatory and enhance immunity of suppressing.Antithrombotic effect: leukocyte and thrombotic relation cause great concern very early.Rich platelet thrombosis position often has leukocyte to gather, and leukocyte produces a large amount of oxygen-derived free radicals and hydrogen peroxide etc. by respiratory burst and activates platelet.Leukocyte and hematoblasticly be attached on inflammation, thrombosis, tissue injury, inflammation is sent out and blood coagulation in play an important role.Investigation Radix Salviae Miltiorrhizae ropes such as Jiang Kaiyu are expressed various cell adhesion molecules to platelet, leukocyte and vascular endothelial cell, comprise that P selects plain (P-selectin), iuntercellular adhesion molecule (ICAM 1), vascular cell adhesion molecule (VCAM-1), E to select the influence of plain (E-selectin).Result of study shows that danshensu is inhibited to leukocyte; Thrombin is caused that the platelet palatelet-selectin is expressed do not see obvious inhibitory action; The inductive VCAM 1 of tumor necrosis factor (TNFd), E selectin express to increase and can produce inhibitory action.In a word, danshensu pair cell factor activation endotheliocyte has inhibitory action, thereby helps protecting blood vessel endothelium, reduces leukocytic sticking.May be one of mechanism of its performance anti-thrombosis function.Ding M etc. has studied the pharmacological action of Radix Salviae Miltiorrhizae extract and the influence that the inductive endothelial permeability of the tumor factor is raise thereof.It is inhibited that the result shows that danshensu raises to the inductive endothelial permeability of the tumor factor, and danshensu can suppress the expression of VEGF (VEGF) simultaneously.
Cortex Moutan has another name called Cortex Moutan, unpeeled CORTEX MOUTAN, bar Cortex Moutan, wooden Radix Paeoniae, and the beginning is stated from Shennong's Herbal, is the dry root bark of Paeoniaceae plant Paeonia suffruticosa.Cortex Moutan acrid in the mouth hardship, cool in nature, function clearing away heat and cooling blood, blood circulation promoting and blood stasis dispelling.Cure mainly the warm febrile disease blood of joining the army, tell nosebleed, send out speckle, abdominalgia with intestinal abscess, skin infection, blood stasis amenorrhea dysmenorrhea, traumatic injury etc.Modern age, pharmacological research showed, Cortex Moutan has functions such as anticoagulation, blood pressure lowering, antiinflammatory, inhibition central nervous system.The main effective ingredient of Cortex Moutan is a paeonol, has the number of significant pharmacologically active, aspect the hemorheological property effect: Ye Zhiyi etc. utilize Microcirculatory Image processing system research paeonol to microcirculation, and the result shows that paeonol has the fastoperation of adding to partial microcirculation.The experimental result of Li Wei etc. shows: paeonol can make packed cell volume, full speckle apparent viscosity, erythrocyte aggregation and platelet adhesion reaction reduction, changes red cell deformability, illustrates that paeonol all has intervention effect in thrombotic each link.Utilizations such as Li Wei are optimized means of micropipette aspiration technique and be studies show that further paeonol has remarkable influence really to erythrocytic morphotropism.
In recent years, China's " apoplexy " is the cerebral embolism of modern medicine, disease sees that dull mind, tongue body harden, speech is puckery late, asophia, facial hemiparalysis, numb limbs and tense tendons, hemiplegia and arteriosclerosis, is common clinical and frequently-occurring disease, and its sickness rate is in rising trend.The curative effect that studies show that blood-activating and stasis-removing treatment apoplexy is sure, and danshensu has definite function of promoting blood circulation to disperse blood clots as the main water-soluble active ingredient of salviamiltiorrhizabung; Paeonol is the main active in the Cortex Moutan; Danshensu and paeonol are important medical material medicines, use very extensive especially in the medicine of apoplexy; To this, the purification high-purity salvianic acid A is significant with the molecule Chinese medicine that the paeonol crude drug becomes to distinguish one from the other for formulating, mechanism of action is clear and definite from Chinese crude drug or natural drug.
Summary of the invention
The objective of the invention is from Radix Salviae Miltiorrhizae, Cortex Moutan, to extract respectively high-purity salvianic acid A and paeonol raw material, and be prepared into the antithrombotic capsule preparations.
For achieving the above object, the technical scheme of employing is that Radix Salviae Miltiorrhizae is through supercritical CO
2Extraction, concentrate, Basifying liquid medicine, precipitate with ethanol, concentrate, technologies such as water is carried, concentrate, saltout, extract, concentrate, extracted with diethyl ether, accent pH value, recrystallization extract acquisition content greater than 95.0% danshensu, and airtight preservation in the inflated with nitrogen light resistant container.Cortex Moutan makes content greater than 96.0% paeonol through technologies such as pulverizing, dipping, ultrasonic, distillation, cold preservation, crystallization, recrystallization.Danshensu is the crystallization of white minute hand shape, and 84～86 ℃ of fusing points are dissolved in methanol, water, are insoluble to chloroform, ether, molecular formula C
9H
10O
5, molecular weight 198.17.Paeonol is white or the glossiness acicular crystal of little yellow, and 50 ℃ of fusing points, water-soluble slightly are dissolved in ethanol, ether, acetone, chloroform, benzene and Carbon bisulfide, molecular formula C
9H
10O
3, molecular weight 166.18.
Description of drawings
Accompanying drawing 1 is the process chart of the preparation method of the purification of high-purity salvianic acid A and microcapsule thereof
Accompanying drawing 2 is process charts of the preparation method of purification of high-purity paeonol and clathrate thereof
The specific embodiment
1, crude drug and reagent
Radix Salviae Miltiorrhizae, Cortex Moutan medical material:, should meet the regulation of statutory standards (carrying out version Chinese Pharmacopoeia in 2005 at present) through check.95% ethanol, 5%NaHCO
3, hydrochloric acid, 80% ethanol, sodium chloride, ether, microcrystalline Cellulose, lactose, low-substituted hydroxypropyl cellulose tertiary butyl-4-hydroxy methyl phenyl ethers anisole, hydroxypropyl emthylcellulose, magnesium stearate, sodium lauryl sulphate.
2, the preparation method of the purification of high-purity salvianic acid A and microcapsule thereof
See Figure of description 1.
3, the preparation method of purification of high-purity paeonol and clathrate thereof
See Figure of description 2.
4, the preparation of compound radix salviae miltiorrhizae essence capsule
Above-mentioned danshensu microcapsule and paeonol clathrate in 1: 1 ratio mixing of its actual weight percentage, are incapsulated, promptly.
5, clinical indication of compound radix salviae miltiorrhizae essence capsule and using method thereof
Compound radix salviae miltiorrhizae essence capsule has blood circulation promoting and blood stasis dispelling, dispelling pathogenic wind and eliminating phlegm, dredge the meridian passage.Cure mainly apoplexy (cerebral thrombosis); Disease sees that dull mind, tongue body harden, speech is puckery late, asophia, facial hemiparalysis, numb limbs and tense tendons, hemiplegia and arteriosclerosis.Using method is each 2-3 grain, 2-3 time on the one; 4 weeks were a course of treatment.
Claims (3)
1, a kind of method of extracting high-purity salvianic acid A from Radix Salviae Miltiorrhizae is characterized in that: the one, and supercritical carbon dioxide extraction, concentrated: extracting pressure 20Mpa, 45 ℃ of extraction temperature, 8h, entrainer uses 95% ethanol, 400ml/h, raw material granularity 40 orders; The 2nd, alkalization extract: in the supercritical carbon dioxide extraction thing, add 5%NaHCO
3, transfer pH value to 6.8; The 3rd, the ethanol extraction with 80% concentrates, and the reuse water extraction concentrates the water extract; The 4th, saltout, add the proper amount of sodium chloride liquid of must saltouing, extract the liquid of saltouing, concentrate, with water intaking layer after the extracted with diethyl ether, transfer pH value to 4.2, obtain crude product, make with extra care, content greater than 95% danshensu raw material; Adopt gelatin encapsulated method to be prepared into microcapsule, the airtight preservation of lucifuge.
2, a kind of method of extracting the high-purity paeonol from Cortex Moutan is characterized in that: the one, and dipping, supersound extraction: pulverize back 40 ℃ of infiltrations of sodium chloride solution, ultrasonic 20 minutes; The 2nd, steam distillation, the water that adds 12 times of amounts distills, and collects 9 times of amounts of medical material distillate; The 3rd, the cold preservation crystallization, distillate cold preservation is spent the night, and filters, and gets crystal; Filtrate adds the sodium chloride with above-mentioned equivalent again, carries out redistillation, and cold preservation is spent the night, and filters, and gets crystal, and two crystals merge; The 4th, dry, in 38 ℃ of following hot air dryings, get content greater than 96% paeonol raw material; Make the paeonol clathrate with beta-schardinger dextrin-, the airtight preservation of lucifuge.
3, a kind of preparation method for the treatment of two capsules of apoplexy is characterized in that: 1: 1 ratio mixing in danshensu microcapsule and paeonol clathrate actual weight percentage composition incapsulates.This product blood circulation promoting and blood stasis dispelling, dispelling pathogenic wind and eliminating phlegm, dredge the meridian passage; Cure mainly apoplexy (cerebral thrombosis); Deng disease.Each 2-3 grain, 2-3 time on the one; 4 weeks were a course of treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100229081A CN101623276B (en) | 2009-06-11 | 2009-06-11 | Compound radix salviae miltiorrhizae essence capsule for treating apoplexy and preparation technique thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100229081A CN101623276B (en) | 2009-06-11 | 2009-06-11 | Compound radix salviae miltiorrhizae essence capsule for treating apoplexy and preparation technique thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101623276A true CN101623276A (en) | 2010-01-13 |
| CN101623276B CN101623276B (en) | 2011-03-30 |
Family
ID=41519371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100229081A Expired - Fee Related CN101623276B (en) | 2009-06-11 | 2009-06-11 | Compound radix salviae miltiorrhizae essence capsule for treating apoplexy and preparation technique thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101623276B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102379864A (en) * | 2011-10-28 | 2012-03-21 | 中国人民解放军第四军医大学 | Compound salvianic acid injection for treating cerebral vascular thrombosis diseases and preparation process thereof |
| CN103705589A (en) * | 2012-09-28 | 2014-04-09 | 香港理工大学 | Cortex moutan microcapsule for treating allergic dermatitis, and preparation method and application thereof |
| CN106478412A (en) * | 2016-10-08 | 2017-03-08 | 贵州景峰注射剂有限公司 | A kind of extracting method of danshensu |
| CN107827737A (en) * | 2017-10-31 | 2018-03-23 | 齐芳 | A kind of alcohol extracting method for reducing danshensu loss |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1098098C (en) * | 1999-11-26 | 2003-01-08 | 化学工业部西南化工研究设计院 | Supercritical CO2 extraction process of the active component in red sage as one Chinese medicine material |
| CN1415303A (en) * | 2002-10-24 | 2003-05-07 | 成都浦泓生物科技开发有限公司 | Red sage root and Tienchi sustained release medication, its preparation method and medicinal application in vascular dementia |
| CN1899388A (en) * | 2005-07-19 | 2007-01-24 | 张彤丽 | Shuangdan soft capsule and its preparing method |
-
2009
- 2009-06-11 CN CN2009100229081A patent/CN101623276B/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102379864A (en) * | 2011-10-28 | 2012-03-21 | 中国人民解放军第四军医大学 | Compound salvianic acid injection for treating cerebral vascular thrombosis diseases and preparation process thereof |
| CN103705589A (en) * | 2012-09-28 | 2014-04-09 | 香港理工大学 | Cortex moutan microcapsule for treating allergic dermatitis, and preparation method and application thereof |
| CN103705589B (en) * | 2012-09-28 | 2015-12-02 | 香港理工大学 | Cortex moutan microcapsule being used for the treatment of allergic dermatitis and its preparation method and application |
| CN106478412A (en) * | 2016-10-08 | 2017-03-08 | 贵州景峰注射剂有限公司 | A kind of extracting method of danshensu |
| CN107827737A (en) * | 2017-10-31 | 2018-03-23 | 齐芳 | A kind of alcohol extracting method for reducing danshensu loss |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101623276B (en) | 2011-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103768534A (en) | Traditional Chinese medicinal composition with anti-tumor activity | |
| CN101623276B (en) | Compound radix salviae miltiorrhizae essence capsule for treating apoplexy and preparation technique thereof | |
| CN104258193A (en) | Drug composition for treating neurasthenia and preventing senile dementia | |
| CN1259085C (en) | Sapid invigorating yang five-recouping capsule and the preparation thereof | |
| CN103405501B (en) | Preparation method of three-component blood-activating and stasis-dissolving capsules | |
| CN105311492A (en) | Medicine for treating coronary atherosclerotic heart disease | |
| CN105031192A (en) | Traditional Chinese medicine preparation for treating influenza and preparation method thereof | |
| CN106334171B (en) | A kind of Chinese medicine preparation and preparation method for being used to repair hepatic injury | |
| CN101112498B (en) | Chinese traditional medicine having functions of promoting blood circulation, relaxing vein and strengthening muscles and bones and method for preparing the same | |
| CN113925946A (en) | Traditional Chinese medicine for soothing liver and relieving depression and preparation method thereof | |
| CN106620402A (en) | Traditional Chinese medicine composition taken after operation of liver cancer and preparation method thereof | |
| CN106938048A (en) | A kind of Chinese medicine preparation for treating cardiovascular and cerebrovascular disease | |
| CN104771456A (en) | Application of bistort rhizome extract in inhibition of tyrosinase activity | |
| CN111643558A (en) | Traditional Chinese medicine for treating thrombus and preparation method thereof | |
| CN102343049A (en) | Chinese medicinal capsules for treating hypertension due to liver-yang hyperactivity | |
| CN102139005B (en) | Medicine for treating cardiovascular and cerebrovascular diseases | |
| CN101301304A (en) | Chinese medicinal composition for treating ischemic stroke and preparation thereof | |
| CN1827138A (en) | Chinese medicine composition prescription for treating cardiovascular and cerebrovascular diseases and preparation technique thereof | |
| CN100475248C (en) | A medicine for treating metrorrhagia and preparation process thereof | |
| CN104398677B (en) | A kind of tartary buckwheat general flavone and Gynostemma Pentaphyllum compound | |
| CN104147219B (en) | Chinese medicine composition of a kind of pain relieving relieving fainting and preparation method thereof | |
| CN107137683A (en) | A kind of medicine for treating apoplexy and application | |
| CN102133332B (en) | Traditional Chinese medicine compound preparation for preventing and curing coronary heart disease and angina and preparation method thereof | |
| CN100515466C (en) | Chinese medicine preparation for treating stroke | |
| CN106421473A (en) | Preparation method of traditional Chinese medicine capable of reducing blood lipid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110330 Termination date: 20160611 |